Monitor for future prospectus supplements that will disclose specific offering terms. The massive size of this shelf relative to market cap suggests potential for significant dilution. Watch for insider selling patterns and upcoming clinical trial data that could trigger an offering.
RCKT drugs
RCKT drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 3 $4.80entry
- T+1 · 9mo ago +0.42%α −0.34% · $4.82
- T+5 · 8mo ago +10.42%α +10.89% · $5.30
- T+20 · 8mo ago −25.42%α −21.01% · $3.58
- T+60 · 6mo ago −37.71%α −48.03% · $2.99
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Rocket Pharmaceuticals has filed a shelf registration (S-3) for up to $400 million in securities, including common stock, preferred stock, debt, warrants, or units. This filing signals potential future dilutive capital raises but does not specify immediate issuance. The company is a small-cap biotech with a market cap of $3 million, recently restructuring to extend its cash runway.
Key Financial Metrics
Key Facts
- Rocket Pharmaceuticals filed an S-3 shelf registration for up to $400,000,000 in securities (common stock, preferred stock, debt, warrants, or units)
- Market cap is only $3 million, meaning the offering could represent over 13,000% of current market value if fully utilized
- No specific offering details provided - this is a registration for potential future issuances
- Company recently implemented a 30% workforce reduction and cut operating expenses by 25% to extend cash runway
- Company is focused on late-stage gene therapy development for rare diseases with high unmet medical need
Financial Impact
Up to $400 million in potential dilutive capital raises, representing over 13,000% of current $3 million market cap
Risk Factors
- Extreme dilution risk given shelf size is 13,000%+ of current market cap
- Biotech clinical trial failure risk for gene therapy programs
- Potential for opportunistic offering at inflated prices if near-term catalysts boost share price
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001140361-26-007341 |
| Document: ny20066752x1_ex4-4.htm | 0001140361-26-007341 |
| CONTEXT: 10-Q (2025-11-06) | 0001193125-25-269474 |
Track record
21 reports on RCKT
4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +42.18% at T+20 after the Jun 12, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.45 Now $2.16 −11.84% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $2.44 Now $2.16 −11.29% settles Dec 4
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $2.44 Now $2.16 −11.48% settles Nov 30
- Oct 6, 20265w ago 8-K Bullish 7/10 Entry $2.54 to $2.57 Now $2.16 −14.79% ▲ +1.38% +2.62% vs SPY
- Sep 15, 20268w ago 8-K Bullish 7/10 Entry $3.41 to $2.30 Now $2.16 −36.66% ▼ −32.55% −35.27% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers